In patients with T2DM who do not have atherosclerotic cardiovascular disease (ASCVD)/indicators of high-risk, HF, or CKD and who need to minimize hypoglycemia and/or promote weight loss, GLP-1 RAs are generally recommended as a second or third-line option as add-on to metformin therapy
Understanding the core differences between semaglutide and tirzepatide helps contextualize why the transition requires careful management of timing, and why the side effect profiles differ
doi: 10.3389/fpsyt.2024.1295766 Received 17 September 2023 Accepted 22 January 2024 Published 09 February 2024 Volume 15 - 2024 Edited by Kiran Veer Sandhu, University College Cork, Ireland Reviewed by Hossein Dabiri, Shahid Beheshti University of Medical Sciences, Iran Sangyong Jung, CHA University, Republic of Korea Padhmanand Sudhakar, Kumaraguru College of Technology, India Updates Copyright 2024 Luqman, He, Hassan, Ullah, Zhang, Rashid Khan, Din, Ullah, Wang and Wang
Collagen Booster
